Clinical trials
Locally Advanced Non-Small Cell Lung Cancer clinical trials
Below are recruiting locally advanced non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 466 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07596121RecruitingPhase 2
Serplulimab for Advanced Lung Cancer in Older Adults
This trial tests a new immunotherapy drug called serplulimab in patients aged 65 and older with advanced non-small cell lung cancer (NSCLC). The drug works by helping your immune system fight cancer cells that have a specific marker called PD-L1.
Xi'an, ShannxiAges 65 years+ - NCT07590531RecruitingPhase 1/Phase 2
Two-Drug Lung Cancer Treatment Study
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07589205RecruitingPhase 1
Testing IBI3028 for Advanced Solid Tumors
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT07579221RecruitingPhase 1/Phase 2
Navlimetostat and Pumitamig for Advanced Lung Cancer
This study tests a combination of two experimental drugs (navlimetostat and pumitamig) for advanced non-small cell lung cancer in patients whose tumors have a specific genetic change called MTAP loss. The drugs are designed to attack cancer cells in a new way and may help patients whose cancer has stopped responding to previous treatments.
Houston, TexasAges 18 years+ - NCT06728865RecruitingPhase 2
Furmonertinib plus Avastin for EGFR+ lung cancer with brain mets
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
Guangzhou, GuangdongAges 15–75 - NCT06668103RecruitingPhase 2
Study of ABSK043 and Firmonertinib for EGFR-mutant lung cancer
This study tests a new combination of two targeted therapies (ABSK043 and firmonertinib) for people with a specific type of advanced lung cancer. It is for patients whose tumors have an EGFR mutation and are PD-L1 positive.
Hefei, AnhuiAges 18 years+ - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Glendale, CaliforniaAges 18 years+ - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Irving, TexasAges 18 years+ - NCT07561723RecruitingPhase 1
IMP3 Vaccine for Advanced Lung Cancer After Treatment Failure
This study tests a new vaccine designed to help your immune system fight advanced lung cancer that has not responded to standard treatments. The vaccine targets a protein called IMP3 found in your cancer cells.
Chengdu, SichuanAges 18 years+ - NCT06734182RecruitingPhase 2
Targeted therapy plus chemo before surgery for HER2-mutant lung cancer
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
GuangzhouAges 18–75 - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+ - NCT07554339RecruitingPhase 3
Calderasib and Durvalumab for Advanced Lung Cancer After Chemotherapy
This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.
Lisle, IllinoisAges 18 years+ - NCT07548060RecruitingPhase 2
New drug combination for advanced lung cancer after prior treatments
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07518160RecruitingPhase 2
JS212 and JS111 for advanced lung cancer with EGFR mutations
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06755684RecruitingPhase 2
Pre-surgery targeted drug combo for EGFR-mutant lung cancer
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Austin, TexasAges 18 years+ - NCT07510724Recruiting
Real-world study of Tislelizumab for lung cancer
This trial collects information on how well the immunotherapy drug Tislelizumab works for different types of lung cancer. It is meant for people whose doctor already decided to prescribe this drug as part of their care.
Sankt Pölten, Lower AustriaAges 18 years+ - NCT07505173RecruitingPhase 2
Targeted radiation plus osimertinib for brain metastases from EGFR-mutant lung cancer
This trial tests adding a brain-sparing radiation technique to the targeted therapy drug osimertinib for people with EGFR-mutant lung adenocarcinoma that has spread to the brain and is causing symptoms. The goal is to see if this combination can better control the brain tumors while protecting the hippocampus, a key memory area.
TianjinAges 18–75 - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT06467383Recruiting
Study of lung cancer care after surgery or radiation
This study is looking back at the medical records of people with early-stage non-small cell lung cancer who had surgery or radiation therapy between 2018 and 2019. The goal is to understand how patients were diagnosed and treated, which may help improve care for others in the future.
San Giovanni Rotondo, FGAges 18 years+ - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced non-small cell lung cancer?
- Yes. Clin2 currently lists 466 recruiting locally advanced non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Lung Non-Small Cell Carcinoma
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.